EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Efficacy and Safety of Hypertonic Saline Therapy in Ambulatory Patients with Heart Failure: The SALT-HF Trial

Marta Cobo Marcos, Rafael de la Espriella, Josep Comín-Colet, Isabel Zegrí-Reiriz, Jorge Rubio Gracia, Jose Luis Morales-Rull, Pau Llàcer, Pablo Díez-Villanueva, Santiago Jiménez-Marrero, Javier de Juan Bagudá, Carolina Ortiz Cortés, Maria Alejandra Restrepo-Córdoba und 7 weitere

European Journal of Heart Failure · 01.10.2024 · 26 (10) · 2118-2128

DOI: 10.1002/ejhf.3390 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Heart Failure, online erschienen am 26.07.2024. Verfasst von Marta Cobo Marcos und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Hospital Universitario Puerta de Hierro, Madrid, Spain. Hauptthemen laut MEDLINE: Heart Failure, Furosemide. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Combination of hypertonic saline solution (HSS) with intravenous loop diuretics has been suggested to improve diuretic response in patients hospitalized for heart failure (HF). The efficacy and safety of this approach in the ambulatory setting remain unexplored. Methods and results In this multicentre, double-blind, randomized study, we allocated ambulatory patients with worsening heart failure (WHF) to a 1-h infusion of intravenous furosemide (ivFurosemide)-HSS versus ivFurosemide. The primary endpoint was the volume of diuresis at 3 h. Secondary endpoints included 3-h natriuresis and weight variation, 7-day congestion data, kidney function and electrolytes, and 30-day clinical events. Overall, 167 participants (median age: 81 years, 30.5% female) were randomized across 13 sites between December 2020 and March 2023. There were no differences in 3-h diuresis between treatments (ivFurosemide-HSS: 1099 ml vs. ivFurosemide: 1103 ml, p = 0.963), 3-h natriuresis (∆ +2.642 mEq/L, p = 0.559), or 3-h weight (∆ +0.012 kg, p = 0.920). Patients in the ivFurosemide-HSS arm experienced significant weight decrease at 7 days (Δ −0.586 kg, p = 0.048). There were no between-treatment differences in clinical congestion score, biomarkers, inferior vena cava diameter, or the presence of lung ultrasound B-lines. At 30 days, 26.5% of the patients in the ivFurosemide-HSS group versus 33.3% in the ivFurosemide group experienced WHF (hazard ratio 0.76, p = 0.330). The incidence of death from any cause or HF hospitalization was 6% of patients in the ivFurosemide-HSS group and 8.3% of patients in the ivFurosemide group (hazard ratio 0.69, p = 0.521). The incidence of worsening kidney function or metabolic derangements was not significantly different in the two arms.

Conclusions

A single infusion of ivFurosemide-HSS did not improve 3-h diuresis or congestion parameters in patients with ambulatory WHF. This therapy showed an appropriate safety profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureFurosemideHumansFemaleMaleSaline Solution, HypertonicDouble-Blind MethodAged, 80 and overAgedTreatment OutcomeInfusions, IntravenousDiureticsSodium Potassium Chloride Symporter Inhibitors

Stichwörter der Autor:innen

Ambulatory heart failureDiuretic treatmentHypertonic saline solutionHypertonic therapyWorsening heart failure

Substanzen

Saline Solution, HypertonicFurosemideDiureticsSodium Potassium Chloride Symporter Inhibitors

Autor:innen und Institutionen

  • Department of Cardiology, Hospital Universitario Puerta de Hierro, Madrid, Spain.
  • Centro de Investigación Biomédica en Red (CIBER Cardiovascular), Madrid, Spain.
  • Department of Cardiology, Hospital Clínico Universitario de Valencia (INCLIVA), University of Valencia, Valencia, Spain.
  • Department of Cardiology, Hospital Universitario de Bellvitge, IDIBELL, Barcelona, Spain.
  • Department of Cardiology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Department of Internal Medicine, Hospital Universitario Lozano Blesa, University of Zaragoza, Aragon Health Research Institute (IIS Aragon), Zaragoza, Spain.

Förderung

  • Instituto de Salud Carlos III

Zitieren

APA

Cobo Marcos, M., de la Espriella, R., Comín-Colet, J., Zegrí-Reiriz, I., Rubio Gracia, J., Morales-Rull, J. L., Llàcer, P., Díez-Villanueva, P., Jiménez-Marrero, S., de Juan Bagudá, J., Ortiz Cortés, C., Restrepo-Córdoba, M. A., Goirigolzarri-Artaza, J., García-Pinilla, J. M., Barrios, E., Del Prado Díaz, S., Montero Hernández, E., Sanchez-Marteles, M., & Núñez, J. (2024). Efficacy and Safety of Hypertonic Saline Therapy in Ambulatory Patients with Heart Failure: The SALT-HF Trial. European Journal of Heart Failure, 26(10), 2118-2128. https://doi.org/10.1002/ejhf.3390

Vancouver

Cobo Marcos M, de la Espriella R, Comín-Colet J, Zegrí-Reiriz I, Rubio Gracia J, Morales-Rull JL, et al. Efficacy and Safety of Hypertonic Saline Therapy in Ambulatory Patients with Heart Failure: The SALT-HF Trial. European Journal of Heart Failure. 2024;26(10):2118-2128. doi:10.1002/ejhf.3390

BibTeX
@article{CoboMarcos2024,
  author = {Cobo Marcos, Marta and de la Espriella, Rafael and Comín-Colet, Josep and Zegrí-Reiriz, Isabel and Rubio Gracia, Jorge and Morales-Rull, Jose Luis and Llàcer, Pau and Díez-Villanueva, Pablo and Jiménez-Marrero, Santiago and de Juan Bagudá, Javier and Ortiz Cortés, Carolina and Restrepo-Córdoba, Maria Alejandra and Goirigolzarri-Artaza, Josebe and García-Pinilla, Jose Manuel and Barrios, Elvira and Del Prado Díaz, Susana and Montero Hernández, Esther and Sanchez-Marteles, Marta and Núñez, Julio},
  title = {Efficacy and Safety of Hypertonic Saline Therapy in Ambulatory Patients with Heart Failure: The SALT-HF Trial},
  journal = {European Journal of Heart Failure},
  year = {2024},
  volume = {26},
  number = {10},
  pages = {2118--2128},
  doi = {10.1002/ejhf.3390}
}
Kostenlos starten →